Skip to main content
Log in

An overnight switch to ropinirole therapy in patients with Parkinson's disease

  • Short Communication
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary.

Patients with Parkinson's disease (n = 68) switched from per-golide or bromocriptine to ropinirole overnight (dose equivalence ratios – 1 : 6 and 10 : 6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine–ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received January 28, 1999; accepted June 30, 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

Canesi, M., Antonini, A., Mariani, C. et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. J Neural Transm 106, 925–929 (1999). https://doi.org/10.1007/s007020050212

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s007020050212

Navigation